EWA
JAZZ icon

Evolution Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Evolution Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-56
Closed -$7K – 395
2021
Q3 		$7K Sell
56
-76
-58% -$11.5K ﹤0.01% 455
2021
Q2 		$23K Hold
132
– – ﹤0.01% 291
2021
Q1 		$22K Sell
132
-10
-7% -$1.65K ﹤0.01% 280
2020
Q4 		$23K Sell
142
-47
-25% -$7K 0.01% 246
2020
Q3 		$27K Buy
189
+14
+8% +$1.74K 0.01% 242
2020
Q2 		$19K Hold
175
– – 0.01% 204
2020
Q1 		$17K Buy
175
+50
+40% +$6.46K 0.01% 162
2019
Q4 		$19K Sell
125
-12
-9% -$1.63K ﹤0.01% 230
2019
Q3 		$18K Buy
137
+12
+10% +$1.61K 0.01% 107
2019
Q2 		$18K Buy
+125
New +$16.8K 0.01% 134

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Evolution Wealth Advisors's JAZZ Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 56 shares — an estimated $7K sold.

Evolution Wealth Advisors first reported a position in JAZZ in Q2 2019 and held it in 10 quarters. The position peaked at $27K in Q3 2020. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 56 Jazz Pharmaceuticals shares in Q4 2021, an estimated $7K.
  • Evolution Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 10 quarters.
  • Evolution Wealth Advisors's Jazz Pharmaceuticals position peaked at $27K in Q3 2020.
  • 454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.